221 related articles for article (PubMed ID: 29471921)
21. Treatment readiness, attitudes toward, and experiences with methadone and buprenorphine maintenance therapy among people who inject drugs in Malaysia.
Vijay A; Bazazi AR; Yee I; Kamarulzaman A; Altice FL
J Subst Abuse Treat; 2015 Jul; 54():29-36. PubMed ID: 25841703
[TBL] [Abstract][Full Text] [Related]
22. Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine.
Meteliuk A; Galvez de Leon SJ; Madden LM; Pykalo I; Fomenko T; Filippovych M; Farnum SO; Dvoryak S; Islam ZM; Altice FL
J Subst Abuse Treat; 2021 Feb; 121():108164. PubMed ID: 33191004
[TBL] [Abstract][Full Text] [Related]
23. Differences in polysubstance use patterns and drug-related outcomes between people who inject drugs receiving and not receiving opioid substitution therapies.
Betts KS; Chan G; McIlwraith F; Dietze P; Whittaker E; Burns L; Alati R
Addiction; 2016 Jul; 111(7):1214-23. PubMed ID: 26857811
[TBL] [Abstract][Full Text] [Related]
24. Balancing access and safety in prescribing opioid agonist therapy to prevent HIV transmission.
Bachireddy C; Weisberg DF; Altice FL
Addiction; 2015 Dec; 110(12):1869-71. PubMed ID: 26464200
[No Abstract] [Full Text] [Related]
25. Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation.
Degenhardt L; Larance BK; Bell JR; Winstock AR; Lintzeris N; Ali RL; Scheuer N; Mattick RP
Med J Aust; 2009 Aug; 191(3):161-5. PubMed ID: 19645647
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis.
Morozova O; Crawford FW; Cohen T; Paltiel AD; Altice FL
Addiction; 2020 Mar; 115(3):437-450. PubMed ID: 31478285
[TBL] [Abstract][Full Text] [Related]
27. Global opioid agonist treatment: a review of clinical practices by country.
Jin H; Marshall BDL; Degenhardt L; Strang J; Hickman M; Fiellin DA; Ali R; Bruneau J; Larney S
Addiction; 2020 Dec; 115(12):2243-2254. PubMed ID: 32289189
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis C virus status awareness and test results confirmation among people who inject drugs in Ukraine.
Iakunchykova O; Meteliuk A; Zelenev A; Mazhnaya A; Tracy M; Altice FL
Int J Drug Policy; 2018 Jul; 57():11-17. PubMed ID: 29655101
[TBL] [Abstract][Full Text] [Related]
29. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
[TBL] [Abstract][Full Text] [Related]
30. Opioid users with comorbid hepatitis C spent more time in agonist therapy: A 6-year observational study in Taiwan.
Chen HM; Lu TH; Chang KC; Lee KY; Cheng CM
Addict Behav; 2017 Sep; 72():133-137. PubMed ID: 28395249
[TBL] [Abstract][Full Text] [Related]
31. Factors associated with physical and sexual violence by police among people who inject drugs in Ukraine: implications for retention on opioid agonist therapy.
Kutsa O; Marcus R; Bojko MJ; Zelenev A; Mazhnaya A; Dvoriak S; Filippovych S; Altice FL
J Int AIDS Soc; 2016; 19(4 Suppl 3):20897. PubMed ID: 27435717
[TBL] [Abstract][Full Text] [Related]
32. Responses among substance abuse treatment providers to the opioid epidemic in the USA: Variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16.
Yang JC; Roman-Urrestarazu A; Brayne C
PLoS One; 2020; 15(3):e0229787. PubMed ID: 32126120
[TBL] [Abstract][Full Text] [Related]
33. Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study: Associations entre le traitement avec la buprénorphine/naloxone et avec la méthadone et l'utilisation de substances non opioïdes dans le trouble lié à l'usage d'opioïdes de type sur ordonnance : analyses secondaires de l'étude OPTIMA.
Bakouni H; Sharafi H; Drouin S; Fortin R; Marsan S; Brissette S; Socias ME; Le Foll B; Lim R; Jutras-Aswad D
Can J Psychiatry; 2024 Apr; 69(4):252-263. PubMed ID: 37899716
[TBL] [Abstract][Full Text] [Related]
34. Concomitant Heroin and Cocaine Use among Opioid-Dependent Patients during Methadone, Buprenorphine or Morphine Opioid Agonist Therapy.
Gastberger S; Baumgartner MR; Soyka M; Quednow BB; Hulka LM; Herdener M; Seifritz E; Mutschler J
Eur Addict Res; 2019; 25(4):207-212. PubMed ID: 31067528
[TBL] [Abstract][Full Text] [Related]
35. Successful transfer of stable patients on opioid agonist therapies from specialty addiction treatment to primary care settings in Ukraine: A pilot study.
Meteliuk A; Galvez S; Fomenko T; Kalandiia H; Iaryi V; Farnum SO; Islam Z; Altice FL; Madden LM
J Subst Abuse Treat; 2022 Mar; 134():108619. PubMed ID: 34579978
[TBL] [Abstract][Full Text] [Related]
36. Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History.
Clark RE; Baxter JD; Aweh G; O'Connell E; Fisher WH; Barton BA
J Subst Abuse Treat; 2015 Oct; 57():75-80. PubMed ID: 25997674
[TBL] [Abstract][Full Text] [Related]
37. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Mattick RP; Breen C; Kimber J; Davoli M
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD002207. PubMed ID: 24500948
[TBL] [Abstract][Full Text] [Related]
38. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study.
Pearce LA; Min JE; Piske M; Zhou H; Homayra F; Slaunwhite A; Irvine M; McGowan G; Nosyk B
BMJ; 2020 Mar; 368():m772. PubMed ID: 32234712
[TBL] [Abstract][Full Text] [Related]
39. The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial.
Bahji A; Bastien G; Bach P; Choi J; Le Foll B; Lim R; Jutras-Aswad D; Socias ME
Can J Psychiatry; 2024 Mar; 69(3):172-182. PubMed ID: 37697811
[TBL] [Abstract][Full Text] [Related]
40. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.
Stein BD; Gordon AJ; Sorbero M; Dick AW; Schuster J; Farmer C
Drug Alcohol Depend; 2012 Jun; 123(1-3):72-8. PubMed ID: 22093488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
